Repository logo
 

Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and aid to differential diagnosis


Change log

Authors

Stylianou, Myrto 
Murphy, Nicholas 
Peraza, Luis R 
Graziadio, Sara 
Cromarty, Ruth 

Abstract

Objective: We investigated for quantitative EEG (QEEG) differences between Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) patients and healthy controls, and for QEEG signatures of cognitive fluctuations (CFs) in DLB. Methods: We analyzed eyes-closed, resting state EEGs from 18 AD, 17 DLB and 17 PDD patients with mild dementia, and 21 age-matched controls. Measures included spectral power, dominant frequency (DF), frequency prevalence (FP), and temporal DF variability (DFV), within defined EEG frequency bands and cortical regions. Results: DLB and PDD patients showed a leftward shift in the power spectrum and DF. AD patients showed greater DFV compared to the other groups. In DLB patients only, greater DFV and EEG slowing were correlated with CFs, measured by the clinician assessment of fluctuations (CAF) scale. The diagnostic accuracy of the QEEG measures was 94% (90.4% - 97.9%), with 92.26% (80.4% – 100%) sensitivity and 83.3% (73.6% - 93%) specificity. Conclusion: Although greater DFV was only shown in the AD group, within the DLB group a positive DFV - CF correlation was found. QEEG measures could classify DLB and AD patients with high sensitivity and specificity.
Significance: The findings add to building literature suggesting that EEG is a viable diagnostic and symptom biomarker in dementia, particularly DLB.

Description

Keywords

dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease dementia, cognitive fluctuations, quantitative electroencephalography

Journal Title

Clinical Neurophysiology

Conference Name

Journal ISSN

1388-2457
1872-8952

Volume Title

129

Publisher

Elsevier

Rights

Attribution 4.0 International
Sponsorship
We thank the Alzheimer’s Society for funding this research as part of the Alzheimer’s Society Doctoral Training center at Newcastle University. This research was also supported the National Institute for Health Research Biomedical Research Centre (NIHR-BRC), the Newcastle Hospitals NHS Charity, the Northumberland, Tyne and Wear NHS Foundation Trust, the Wellcome Trust (grant numbers: BH120812, BH120878) and by the Alzheimer’s Research UK. S.G. was supported by the NIHR MedTech In vitro diagnostic Co-operatives scheme (ref MIC-2016–014).